The Filing Desk

EyePoint

EYPT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

EYPT · Last close · November 19, 2026
$0.26
Value EyePoint yourself

EyePoint's revenue fell 27.5% to $31 million in fiscal 2025. Its operating margin was −776.0%, down from −337.1% a year earlier. Free cash flow was −$243 million. The diluted share count rose 30.1%.

EyePoint, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001193125-26-093917 Updated
Revenue
$31M
27.5%
Operating margin
−776.0%
438.9 pts
Net income
−$232M
 
Free cash flow
−$243M
 
Return on equity
−72.2%
28.8 pts
Market cap
$24M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-10), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What EyePoint does

EyePoint is a clinical-stage biopharmaceutical company, meaning its drug candidates are still being tested and none of its pipeline products is approved. It works on treatments for serious retinal diseases, using its Durasert E technology, a tiny dissolving insert that releases a drug inside the eye over time and is placed with a standard injection in a doctor's office.

Its main product candidate, DURAVYU, combines a drug called vorolanib with that technology to treat diseases driven by a protein called VEGF. It is in Phase 3 trials for wet age-related macular degeneration, and in Phase 3 trials for diabetic macular edema. Enrollment in the wet AMD trials is complete, with data expected beginning in mid-2026. Its other programs include EYP-2301 and razuprotafib.

The company is based in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. It sold the eye product DEXYCU from 2019 to 2023.

Its biggest risks, as it describes them

  • Needing more money, which could force it to cut back its operations.
  • Losses since its start and no assurance it will ever be profitable.
  • Relying heavily on one candidate, DURAVYU, which is still in trials.
  • Clinical trials that are delayed, fail or give results that later change.
  • A 2022 subpoena from the U.S. Attorney's Office about sales and marketing practices for DEXYCU.
From EyePoint's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

EyePoint lost money in fiscal 2025: a net loss of $232 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments212145331371306
Debt incl. finance leases3740———
Net debt (negative means net cash)−175−104———
Net debt to EBITDA—————
Debt to equity0.2x0.4x———
Interest coverage−10.1x−31.2x−60.2x−10,418.1x−7,376.8x
Current ratio10.1x5.0x5.5x7.8x8.9x
Quick ratio9.9x4.9x5.4x7.8x8.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project EyePoint's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What EyePoint says to expect

  • Cash runwayWe expect the cash, cash equivalents, and marketable securities as of September 30, 2026, together with the additional $10 million of capital raised subsequent to quarter-end pursuant to our “at-the-market” equity facility and with anticipated operational adjustments, will enable us to fund operations into late third quarter of 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $71,983 of EyePoint shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 18, 2026Karen L. ZaderejDirectorBought10,600$4.93$52,258Form 4
Mar 16, 2026Jay S. DukerPresident and CEO, DirectorBought1,500$13.15$19,725Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 407.7%−307.0%−803.4%
Altman Z''0.110.41−3.58
Accruals ratio−27.1%−1.2%2.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put EyePoint side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
EyePointFY25−27.5%−776.0%−775.8%———
Foghorn TherapeuticsFY2536.8%−279.5%−278.7%——2Compare
VerastemFY25209.1%−550.3%————Compare
ScilexFY25−46.5%−1,143.7%12.2%——3Compare
NanobiotixFY25—−33.2%−104.2%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue28320343741464331
Revenue growth−93.9%365.4%−60.7%587.8%69.1%7.3%12.1%11.1%−6.0%−27.5%
Gross profit——————————
Research and development1415161517285065133221
Operating income−22−19−26−48−37−55−100−75−146−243
Net income−22−18−53−57−45−58−102−71−131−232
Diluted EPS (US$)−6.80−5.20−11.50−5.44−3.54−2.03−2.74−1.82−2.32−3.17
Diluted shares (millions)34510132937395673
Cash flow
Cash from operations−16−20−22−57−14−50−652−126−240
Capital expenditure0000002443
Free cash flow−16−21−22−57−15−50−67−2−130−243
Dividends paid0000000000
Share buybacks0000000000
Acquisitions00170000000
Stock-based compensation22356714123728
Balance sheet at fiscal year end
Cash and short-term investments29—392245212145331371306
Debt incl. finance leases—01747383740———
Total assets3219727392263180355418364
Total liabilities1156065737984898258
Shareholders' equity21131281818496266336306
Margins and ratios
Gross margin——————————
Operating margin−1,344.1%−246.4%−887.3%−235.0%−108.3%−149.6%−240.7%−163.1%−337.1%−776.0%
Net margin−1,330.1%−245.2%−1,795.7%−278.9%−131.8%−158.1%−247.0%−153.8%−302.4%−739.4%
Free cash flow margin−1,014.1%−273.7%−743.5%−279.5%−43.0%−136.0%−162.2%−3.5%−301.1%−775.8%
Rule of 40 (growth + FCF margin)−1,108.0%91.6%−804.2%308.3%26.1%−128.8%−150.1%7.7%−307.0%−803.4%
Return on capital———−321.0%−130.5%—————
Return on equity−97.4%−108.0%−425.0%−567.5%−337.9%−57.6%−72.8%−39.0%−43.4%−72.2%
Return on assets−67.3%−73.5%−117.7%−78.5%−55.1%−32.9%−46.1%−26.4%−33.8%−59.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: EyePoint's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with EyePoint.